Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
|Slideshows|June 4, 2018
Obesity Weighs on Outcomes in Women With SLE
A potentially modifiable target for improving outcomes in patients with lupus.
Advertisement
Reference1. Patterson SL, Schmajuk G, Jafri K, Yazdany J, Katz P. Obesity independently associates with worse patient-reported outcomes in women with systemic lupus erythematosus. Arthritis Care Res. 2018 May 8. doi: 10.1002/acr.23576. [Epub ahead of print]
Advertisement
Related to this article
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.
A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.
Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.
Advertisement
Advertisement